Rapid Pain and Skin Improvement of Chronic Hand Eczema with Delgocitinib Cream

Abstract

Chronic hand eczema (CHE) is a common inflammatory dermatosis affecting up to 10% of the general population and is associated with pain, impaired hand function, and reduced quality of life. Despite its prevalence and morbidity, effective and well-tolerated treatment options remain limited. Delgocitinib 2% cream, a recently FDA-approved topical nonsteroidal pan–Janus kinase (JAK) inhibitor, has demonstrated efficacy across multiple CHE subtypes in clinical trials.

We report a case of rapid and complete symptomatic remission in a patient with CHE presenting with fingertip fissures, edema, erythema, moderate pain (5/10), and mild pruritus (1/10) following initiation of delgocitinib monotherapy. Marked clinical improvement with complete resolution of both pain and itch was observed within four days of treatment initiation, with continued cutaneous healing and sustained symptom control thereafter. This case highlights the potential of topical pan-JAK inhibition to rapidly improve both objective disease features and patient-reported outcomes, particularly pain and pruritus, which substantially contribute to CHE-related quality-of-life impairment.